=Pfizer (PFE) reported earnings on Tue 29 Oct 19 (b/o)

Pfizer beats by $0.14, beats on revs; raises FY19 EPS guidance above consensus, increases midpoint of revenue outlook 

Reports Q3 (Sep) earnings of $0.75 per share, excluding non-recurring items, $0.14 better than the S&P Capital IQ Consensus of $0.61; revenues fell 4.6% year/year to $12.68 bln vs the $12.37 bln S&P Capital IQ Consensus.

"Following the expected close of the Upjohn-Mylan transaction next year, Pfizer RemainCo will be a smaller, science-based company with a singular focus on innovation. We expect Pfizer RemainCo will be positioned to deliver revenue and Adjusted diluted EPS growth that is among the industry leaders while continuing to allocate significant capital directly to shareholders, primarily through dividends."

Co raises guidance for FY19, sees EPS of $2.94-3.00 (Prior $2.76-2.86), excluding non-recurring items, vs. $2.82 S&P Capital IQ Consensus; sees FY19 revs of $51.2-52.2 bln (Prior $50.5-52.5 bln) vs. $51.47 bln S&P Capital IQ Consensus.